Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 20 April 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Adjuvant chemotherapy delays pancreatic cancer recurrence

Postoperative gemcitabine delays the recurrence of pancreatic cancer after complete resection, reports this week's Journal of the American Medical Association.

News image

fiogf49gjkf04

The role of adjuvant therapy in resectable pancreatic cancer is still uncertain, and no recommended standard exists.

Dr Helmut Oettle and colleagues from Germany evaluated whether adjuvant chemotherapy with gemcitabine after resection of pancreatic cancer improves disease-free survival by 6 months or more.

The research team conducted an open, multicenter, randomized controlled phase 3 trial with stratification for resection, tumor, and node status.

The study was conducted from 1998 to 2004 in outpatient settings at 88 academic and community-based oncology centers in Germany and Austria.

A total of 368 patients with gross complete resection of pancreatic cancer, and no prior radiation or chemotherapy were enrolled into 2 groups.

The team randomized 179 patients received adjuvant chemotherapy with 6 cycles of gemcitabine on days 1, 8, and 15 every 4 weeks, or 175 controls.

The researchers' primary end point was disease-free survival.

Disease-free survival at 3 years was 24% with gemcitabine
Journal of the American Medical Association

Secondary end points were overall survival, toxicity, and quality of life.

The research team's survival analysis was based on all eligible patients.

More than 80% of patients had complete resection.

The researchers found that the median number of chemotherapy cycles in the gemcitabine group was 6.

The team noted grade 3 or 4 toxicities rarely occurred with no difference in quality of life between groups.

During median follow-up of 53 months, 74% of patients in the gemcitabine group, and 92% of patients in the control group developed recurrent disease.

The team identified that the median disease-free survival was 13 months in the gemcitabine group, and 7 months in the control group.

Estimated disease-free survival at 3 and 5 years was 24% and 17% in the gemcitabine group, respectively.

The researchers found that disease-free survival at 3 and 5 years in the control group was 8% and 6%, respectively.

Subgroup analyses showed that the effect of gemcitabine on disease-free survival was significant in patients with either gross complete resection.

The team noted no difference in overall survival between the gemcitabine groups, and the control group.

The research team observed that the estimated survival was 34% at 3 years, and 23% at 5 years in the gemcitabine group.

The researchers noted that the estimated survival was 21% at 3 years, and 12% at 5 years.

Dr Oettle's concludes, “Postoperative gemcitabine significantly delayed the development of recurrent disease after complete resection of pancreatic cancer compared with observation alone.”

“These results support the use of gemcitabine as adjuvant chemotherapy in resectable carcinoma of the pancreas.”

JAMA 2007: 297: 267-77
18 January 2007

Go to top of page Email this page Email this page to a colleague

 20 April 2018 
Obesity and physical activity in diverticulosis
 20 April 2018 
Worldwide H.pylori prevalence
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 20 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 19 April 2018 
Fibrosis in patients with chronic hepatitis B
 19 April 2018 
c-Myc expression and pancreatic cancer
 19 April 2018 
Olmesartan prescription in the USA
 18 April 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 18 April 2018 
Hep C treatment for sustained virologic response
 18 April 2018 
Endoscopic necrosectomy reduces risk of death 
 17 April 2018 
Colorectal cancer screening and ethnic inequities
 17 April 2018 
Training programs should consider radiation education for advanced endoscopy fellows
 17 April 2018 
Aspirin and pancreatic cancer
 16 April 2018 
Surgery for colorectal polyps has increased 
 16 April 2018 
Advanced fibrosis can be ruled out in primary health care patients
 16 April 2018 
Antibiotic use and colorectal adenoma
 13 April 2018 
Colorectal cancer cell lines
 13 April 2018 
Infliximab and corticosteroid-free clinical remission in Crohn's
 13 April 2018 
Teduglutide for children with short bowel syndrome
 12 April 2018 
Prescriptions for opiate drugs amongst primary care patients with IBD
 12 April 2018 
Lower GI bleeding related to comorbidity
 12 April 2018 
non–Clostridium difficile bacterial infections in IBD
 11 April 2018 
Physician perception of IBD trial results
 11 April 2018 
Bile acid deficiency in IBS 
 11 April 2018 
Stem cell therapy for fistulas in Crohn's
 10 April 2018 
Overweight in childhood and type 2 diabetes
 10 April 2018 
immunoglobulin G associates with clinical features of IBD
 10 April 2018 
T-cells repertoires in celiac disease
 09 April 2018 
Biomarker tests for colorectal cancer screening
 09 April 2018 
Fecal transplantation in C. difficile infection and treatment outcome 
 09 April 2018 
No weigh-loss drug improved all cardiometabolic risk factors
 06 April 2018 
Colonoscopy and colorectal cancer mortality
 06 April 2018 
Eosinophilic esophagitis and health-related quality of life
 06 April 2018 
Microbiome in athletes vs sedentary subjects
 05 April 2018 
Laparoscopic Nissen fundoplication for GERD treatment
 05 April 2018 
Random biopsies for neoplasia in IBD
 05 April 2018 
Scoring system identifies cancer risk in Barrett's
 04 April 2018 
Alpha‐1 antitrypsin deficiency and liver disease
 04 April 2018 
PPI and risk of stroke
 04 April 2018 
Adjuvant chemotherapy for advanced colon cancer
 29 March 2018 
Prevention of metachronous gastric cancer
 29 March 2018 
Acute lower GI bleeding
 28 March 2018 
Decision aid used by IBD patients
 28 March 2018 
Transition for young adults with IBD
 28 March 2018 
Amitriptyline in functional dyspepsia
 27 March 2018 
Emergency department utilization for IBD 
 27 March 2018 
Management of hemorrhoids in the USA
 27 March 2018 
Adult ulcerative colitis
 26 March 2018 
Biological therapy response in IBD 
 26 March 2018 
Obesity and diverticulosis
 26 March 2018 
Practice guidelines for chronic constipation
 23 March 2018 
Health-related quality of life in eosinophilic esophagitis
 23 March 2018 
Genetics and chronic liver disease
 23 March 2018 
Global prevalence of H.pylori
 22 March 2018 
H. pyloris and gastric cancer
 22 March 2018 
Pancreatitis after IBS treatment 
 22 March 2018 
Mechanisms of action in patients with IBS
 21 March 2018 
Panel markers for early detection of colon cancer

 21 March 2018 
Blood test differentiates celiac disease
 21 March 2018 
Patient characteristics and colonoscopy preparation

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us